Aurora Cannabis Inc. (the “Company” or “Aurora”) (ACB.V) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) and Radient Technologies (“Radient”) (RTI.V) are pleased to provide an update on their previously announced collaboration arrangements.
As previously announced, the parties have entered into a memorandum of understanding (“MOU”) to evaluate an exclusive partnership for the Canadian market with regard to the joint development and commercialization of superior and standardized cannabinoid extracts.
In accordance with the memorandum of understanding (“MOU”), the parties, on January 4, 2017 , entered into a joint venture research agreement pursuant to which Radient and Aurora are working to confirm the effectiveness of Radient’s MAPTM technology for cannabis extraction. Initial work under the study is ongoing.
As part of the MOU, Aurora will, subject to certain conditions precedent being satisfied, invest up to $2 million into Radient by means of a convertible debenture (the “Debenture”). The Debenture will have a term of 2 years, bear interest at 10% per annum and will be convertible into units (each, a “Unit”) of Radient at a conversion price of $0.14 per Unit. Each Unit will be comprised of one common share of Radient and one share warrant, exercisable within 24 months, for one common share of Radient at an exercise price of $0.33 per warrant.
Aurora and Radient will provide a further update at such time as Aurora has made its final determination in regards its investment in the Debenture.
Radient extracts natural compounds from a range of biological materials using its proprietary “MAPTM” natural product extraction technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its initial 20,000 square foot manufacturing plant in Edmonton, Alberta , Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Visit www.radientinc.com for more information.
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada . Aurora trades on the TSX Venture Exchange under the symbol “ACB”.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.